Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 245 is a protein-coding gene product predicted to be a membrane-localized protein, expressed in multiple tissues and cell types, including cytoplasmic and membranous compartments. Genetic association studies have linked variants in TMEM245 (also known as C9orf5 or CG-2) to negative symptoms in schizophrenia, suggesting a possible, but not yet mechanistically understood, role in neural or synaptic pathways. TMEM245 is also implicated in rare disorders such as developmental and epileptic encephalopathy 37 and hereditary sensory and autonomic neuropathy type III. The precise molecular function remains unknown, and it is not currently recognized as a therapeutic target. No drugs are known to interact with TMEM245, and it is not used as a biomarker in clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 245 (TMEM245).